Furthermore, we investigated the impact of varying radiation doses and drug holiday schedules on therapeutic efficacy, with the intention of developing novel therapeutic strategies for patients with KRAS-mutated lung cancers. This evidence concerns the gene KRAS and lung carcinoma.